RxDoctor Payments Data

David Hopper, MD

Family Medicine · Oxford, ALNPI 1861497455

Payments from drug & device makers

$2,728in general payments, 2019–2025

Across 168 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$217
  • Boehringer Ingelheim$155
  • AbbVie$115
  • Pfizer$104
  • Amgen$97
  • plus $885 from 19 others

What the payments were for

  • Food & beverage$2,728100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,728 in reported general payments places this provider in the 70th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$174,531
Medicare patients
402
Services billed
6,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin122$90,799
JanuviaSitagliptin Phosphate38$53,380
OzempicSemaglutide42$51,902
MounjaroTirzepatide24$36,259
RybelsusSemaglutide23$30,016
EliquisApixaban25$27,766
FarxigaDapagliflozin Propanediol31$24,165
TrulicityDulaglutide14$18,094
Repatha SureclickEvolocumab19$14,585
JanumetSitagliptin Phos/Metformin Hcl21$10,300
XareltoRivaroxaban16$8,272
Atorvastatin Calcium557$8,075
Janumet XrSitagliptin Phos/Metformin Hcl14$7,393
LinzessLinaclotide12$7,344
TradjentaLinagliptin13$6,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$155$97,275135 claims
Novo NordiskOzempic, Rybelsus$1,155$81,91865 claims
MerckJanuvia, Janumet, Janumet Xr$71$71,07473 claims
Lilly USA, LLCMounjaro, Trulicity$69$54,35338 claims
PfizerEliquis$104$27,76625 claims
AstraZenecaFarxiga$217$24,16531 claims
AbbVieLinzess, Synthroid$115$12,01158 claims
Johnson & JohnsonXarelto$40$8,27216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Oxford

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →